pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
Lumacaftor Plus Ivacaftor Combination
Phase 3 · small molecule · Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Lumacaftor Plus Ivacaftor Combination for Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).
Internal code VX12-809-105
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Status
- completed
- Trials
- 1